1887

oa Journal of Endocrinology, Metabolism and Diabetes in South Africa - Position paper on the indications for the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis : NOFSA position paper

Volume 14, Issue 1
  • ISSN : 1608-9677
  • E-ISSN: 2220-1009

 

Abstract

Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands which, amongst many varied physiological effects, serves to maintain normal serum calcium levels. In fulfilling this function, the hormone interacts with its receptors in a number of tissues, including bone. One effect in bone is to stimulate preosteoblast formation and differentiation to mature functional osteoblasts and to prevent their apoptosis. Cytokines subsequently released by the osteoblasts then stimulate osteoclastic activity, bone breakdown and release of calcium into the circulation. Continued high level exposure of bone to PTH will result in eventual bone loss, but intermittent exposure will have an anabolic effect - fact which makes this peptide useful as a potent treatment for osteoporosis. Teriparatide is a 34 amino acid peptide which mimics the physiological effects of PTH and is registered in South Africa for the treatment of established osteoporosis with or without vertebral fractures in post menopausal women and in men. The intact human recombinant molecule PTH (1-84) is not available in South Africa and will not therefore be included in this discussion.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/m_jemdsa/14/1/EJC64179
2009-01-01
2017-11-18

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error